natgillin/translations-raw huggingface dataset:
A milky-white liquid of low viscosity with a faint characteristic odour, free of visible particulate matter.
Mlečno bela tekočina, nizke viskoznosti, z rahlo značilnim vonjem, brez vidnih delcev.
One treatment box of Prevora Dental solution contains 6 Type 1 glass vials of Stage 1 chlorhexidine coating along with 6 Type 1 glass vials of Stage 2 sealant coating.
Škatla Prevora Dental solution za eno zdravljenje vsebuje šest tipa 1 stekleničk faze 1 klorheksidinskega premaza ter šest tipa 1 stekleničk faze 2 tesnilnega premaza.
HOW TO STORE PREVORA
KAKO HRANITI PREVORA
Step #8.
Korak 8.
Avoid application of Prevora 100 mg/ml Dental Solution to the soft tissues.
Izogibajte se uporabi Prevora 100 mg/ml Dental Solution na mehkih tkivih.
This topical, temporary coating on your teeth is applied by your dental professional in a short appointment in the dental office.
Ta lokalni, začasni premaz nanese na vaše zobe vaš zobozdravnik ob obisku v ordinaciji.
Prevora 100 mg/ml Dental Solution should not be applied immediately following use of an oil-based prophylactic paste or up to 3 days following application of a fluoride dental varnish.
Prevora 100 mg/ml Dental Solution naj se ne uporablja neposredno po uporabi profilaktične paste na oljni osnovi ali od uporabe fluoridnega zobnega laka pa naj preteče vsaj 3 ure.
Prevora 100 mg/ml Dental Solution should be used with caution in patients with a history of asthma or eczema.
Prevora 100 mg/ml Dental Solution je potrebno uporabljati previdno pri bolnikih z anamnezo astme ali ekcemom.
Chlorhexidine, the active substance in Prevora, can also cause staining of the teeth; however, when chlorhexidine is applied as a topical, temporary dental coating, staining is rare.
Klorheksidin, aktivna substanca v Prevora, lahko povzroči tudi obarvanje zob, čeprav se to zelo redko dogaja, kadar je klorheksidin nanešen lokalno, kot začasen zobni premaz.
The ingredients are Ammonio methacrylate copolymer dispersion, Type B and Triethyl citrate What Prevora looks like and contents of the pack:
Sestavini sta amonijev metakrilat kopolimer disperzija, tip B in trietilcitrat Kako izgleda Prevora in vsebina paketa: dentalna raztopina
To be used in dental offices only by dental professionals.
Zdravilo se lahko uporablja samo v zobozdravstvenih ambulantah pod adzorom zobozdravnika.
Since many drugs are excreted during lactation and there have not been any studies performed using Prevora 100 mg/ml Dental
Ker se mnogo zdravil med dojenjem izloča v mleko in ker še ni bila glede uporabe Prevora 100 mg/ml Dental
Prevora 100 mg/ml Dental Solution is administered topically to the entire dentition of the patient using a cotton pellet or fine paint brush.
Prevora 100 mg/ml Dental Solution se uporablja lokalno na celotnem zobovju bolnika s pomočjo bombažne pelete ali mehkega čopiča.
Hypersensitivity to chlorhexidine, Sumatra benzoin or ethanol.
Preobčutljivost na klorheksidin, sumatra benzoin ali etanol.
Prevora 100 mg/ml Dental Solution Chlorhexidine diacetate
Prevora 100 mg/ml Dental Solution klorheksidin diacetat
Chlorhexidine, the active substance in Prevora , can stain the teeth when used in a mouth rinse or gel; however, in controlled clinical studies and dental office use, the occurrence of tooth staining by the Prevora dental coating is rare.
Klorheksidin, aktivna substance v Prevora, lahko povzroči tudi obarvanje zob, kadar se uporablja v ustnem izpiralu ali gelu, čeprav klinične študije in zobozdravstvena praksa kažejo, da se to ob uporabi Prevora redko dogaja.
There is no experience with over-dosage with Prevora 100 mg/ml Dental Solution.
Ni izkušenj z prevelikimi odmerki Prevora 100 mg/ml Dental Solution.
• The dried Prevora coating will begin coming off the teeth during the next meal.
• se bo posušen premaz Prevora ob naslednjem obroku pričel snemati z zob.
Solution in nursing mothers, it is recommended that Prevora 100 mg/ml Dental Solution should not be applied if the mother is nursing.
Solution pri doječih materah opravljena nobena raziskava, se priporoča, da se Prevora 100 mg/ml Dental Solution ne uporablja, če mati doji.
Step #1.
Korak 1.
If you receive a professional cleaning, it should be done 7 days after the Prevora treatment.
V kolikor se odločite za strokovno čiščenje zob, storite to najmanj sedem dni po obravnavi s Prevora.
Stage 2 sealant coating
Faza 2 tesnilen premaz
Then resume brushing with a new tooth brush and brush 2 to 3 times daily with fluoride toothpaste.
Nato naj nadaljuje s ščetkanjem z novo ščetko ter flouroidno zobno pasto dva do trikrat na dan.
Discoloration of the teeth and silicate or composite restorations
Splošne težave in stanje na mestu uporabe prehodna občutljivost zob in izguba okusa obarvanje zob in silikatnih ali sestavljenih obnovitev
Figure 3: Apply Prevora Stage 1 chlorhexidine coating with a fine brush to the gingival margin, followed by Prevora Stage 2 sealant coating using the same techniques.
Slika 3: Nanesite Prevora faza 1 klorheksidinski premaz z majhnim čopičem pod rob dlesni, nato z uporabo iste tehnike nanesite še Prevora faza 2 tesnilni premaz.
Dip cotton pellet or fine brush in vial and then apply pellet or brush to tooth surfaces.
Namočite bombažno peleto ali mehak čopič v stekleničko z zdravilom in ga nato nanesite na zobno površino.
The chlorhexidine coating is a clear, slightly brownish solution with a noticeable scent, free of any floating particles in the solution.
Klorheksidinski premaz je prozorna, rahlo rjavkasta raztopina z opaznim vonjem, brez plavajočih delcev v raztopini.
Stage 1 chlorhexidine coating: Sumatra benzoin Ethanol
Faza 1 klorheksidinski premaz: sumatra benzoin etanol
Step #11.
Korak 11.
• If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
• Če pride do resnih stranskih učinkov, ali če opazite stranski učinek, ki v navodilih za uporabo ni naveden, se, prosimo, obrnite na svojega zobozdravnika.
PHARMACEUTICAL FORM AND CONTENTS Dental solution
FARMACEVTSKA OBLIKA dentalna raztopina
BEFORE YOU ARE TREATED WITH PREVORA
PREDEN PRIČNETE ZDRAVLJENJE S PREVORA
Stage 2: ammonio methacrylate copolymer dispersion, Type B and triethyl citrate
Faza 2: amonijev metakrilat kopolimer disperzija, tip B in trietilcitrat
Then to resume flossing daily.
Nato naj nitka na dnevni osnovi.
Stage 1 chlorhexidine coating:
Faza 1 klorheksidinski premaz:
Figure 1 Application of Prevora 100 mg/ml Dental Solution
Slika 1 Nanos Prevora 100 mg/ml Dental Solution
Step #5.
Korak 5.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Each vial contains 1 ml of stage 1 chlorhexidine coating OTHER
VSEBINA PO TEŽI, PROSTORNINI ALI ENOTI Ena steklenička vsebuje 1 ml faza 1 klorheksidinskega premaza DRUGO Pred uporabo preberite navodila za uporabo.
Then you resume brushing with a new brush 2 to 3 times daily with fluoride tooth paste.
Nato nadaljujte s ščetkanjem z novo ščetko ter flouroidno zobno pasto dva do trikrat na dan.
• The dried Prevora coating will begin coming off the teeth during the next meal
• se bo posušen premaz Prevora ob naslednjem obroku pričel snemati z zob
Step #10.
Korak 10.
Step #2.
Korak 2.
If dentures are worn, clean and disinfect at home prior to use.
Če uporabljate zobno protezo, jo redno čistite in dezinficirajte pred uporabo.
Step #9.
Korak 9.
Step #6.
Korak 6.
Stage 1 chlorhexidine coating
Faza 1 klorheksidinski premaz
The other ingredients are Sumatra benzoin and Ethanol
Pomožni snovi sta sumatra benzoin in etanol.
Driving and using machines Prevora has not been shown to affect driving.
Prevora se ni pokazala, da bi imela vpliv na vožnjo.
Do not eat hard foods (e.g. meat, apples) for at least 4 hours after treatment.
Ne jejte trde hrane (npr. meso, jabolka) najmanj štiri ure po obravnavi.
Step #7.
Korak 7.
No controlled studies have been carried out to ascertain if there are any adverse reactions when Prevora 100 mg/ml Dental Solution is applied to the dentition of women of childbearing potential, or to the dentition of expectant or breast feeding mothers.
Kontroliranih študi, ki bi pokazale neželene učinke zdravila Prevora 100 mg/ml Dental Solution pri dentalni uporabi na zobovju žensk v rodni dobi oziroma nosečnic ali doječih mater, niso izvedli.
A clear, slightly brownish solution with a characteristic odour, free of visible particulate matter.
Prozorna, rahlo rjavkasta raztopina, z značilnim vonjem, brez vidnih delcev.
• Do not chew gum for at least 24 hours.
• naj ne žvečite žvečilnega gumija vsaj 24 ur.
Step #3.
Korak 3.
The cotton pellet or brush is dipped into the Prevora 100 mg/ml Dental solution and thereafter is applied to the tooth surfaces (Figure 1).
Bambažno peleto ali čopič se namoči v Prevora 100 mg/ml Dental Solution in raztopino nato nanese na zobno površino.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml of Prevora Dental Solution (Stage 1 chlorhexidine coating) contains chlorhexidine diacetate 100mg
KAKOVOSTNA IN KOLIČINSKA SESTAVA 1 ml zdravila Prevora dentalna raztopina (faza 1 klorheksidinskega premaza) vsebuje 100 mg klorheksidin diacetata.
Step #4.
Korak 4.
Do not brush your teeth for 24 hours after this treatment.
Ne ščetkajte zob najmanj 24 ur po obravnavi.
HOW YOU ARE TREATED WITH PREVORA
KAKO POTEKA ZDRAVLJENJE S PREVORA
Then you resume flossing daily.
Nato nitkajte na dnevni osnovi.
100 mg/ml Dental solution, chlorhexidine diacetate Stage 2 Sealant coating
100 mg/ml zobna raztopina, klorheksidinski diacetat Faza 2 tesnilni premaz
Skin and subcutaneous tissues disorders
FARMACEVTSKA OBLIKA IN VSEBINA dermalna raztopina
• You should not chew gum for at least 24 hours.
• naj ne žveči žvečilnega gumija vsaj 24 ur;
• Do not floss for 3 days after treatment.
• naj ne uporabljate zobne nitke tri dni po obravnavi.
Do not chew gum for at least 24 hours.
Ne žvečite žvečilnega gumija vsaj 24 ur po obravnavi.
Ammonio methacrylate copolymer dispersion, Type B Triethyl citrate
Faza 2 tesnilni premaz: amonijev metakrilat kopolimer disperzija, tip B trietilcitrat
• You should not brush your teeth for 24 hours after treatment.
• naj si ne umiva zob prvih 24 ur po zdravljenju.
Each 1 ml of Prevora Dental Solution (Stage 1 chlorhexidine coating) contains chlorhexidine diacetate 100 mg.
NAVEDBA O AKTIVNI(H) SUBSTANCI(AH) 1 ml Prevora Dental Solution (faza 1 klorheksidinskega premaza) vsebuje 100 mg klorheksidinskega diacetata.
Do not floss your teeth for 3 days following this treatment.
Ne uporabljate zobne nitke vsaj tri dni po obravnavi.
Figure 2: Tray set up for Stage One Stage 1 chlorhexidine coating and Stage 2 sealant coating treatments.
En faza 1 klorheksidinski premaz in faza 2 tesnilen premaz.
PACKAGE LEAFLET
Odmerjanje
Prevora 100 mg/ml Dental Solution
Prevora 100 mg/ml denalna raztopina
Prevora 100 mg/ml Dental Solution contains: Stage 1 chlorhexidine coating:
Prevora 100 mg/ml Dental Solution vsebuje: Faza 1 klorheksidinski premaz: klorheksidin diacetat sumatra benzoin etanol
Objectionable, bitter taste when Prevora 100 mg/ml Dental Solution comes into contact with the saliva or oral mucosa
Bolezni kože in podkožnega tkiva rdečica in/ali začasno zbadajoč občutek na ustni sluznici neprijeten, grenak okus, ko pride Prevora 100 mg/ml Dental Solution v stik s slino ali ustno sluznico
• To avoid eating hard foods (e.g. meat, apples) for at least 4 hours after treatment.
• naj ne uživa trde hrane (npr. meso, jabolke) vsaj štiri ure po obravnavi.
MA # Read the package leaflet before use.
Pred uporabo preberite navodila za uporabo.
• You should avoid eating hard foods (e.g. meat, apples) for at least 4 hours after treatment.
• naj ne uživate trde hrane (npr. meso, jabolke) vsaj štiri ure po obravnavi.
How you are treated with Prevora.
Kako poteka zdravljenje s Prevora.
• They should avoid eating hard foods (e.g. meat, apples) for at least 4 hours after treatment
• naj ne uživa trde hrane (npr. meso, jabolke) vsaj štiri ure po obravnavi;
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
DATUM PRVOTNEGA DOVOLJENJA/OBNOVITVE DOVOLJENJA
The active substance is Chlorhexidine diacetate.
100 mg/ml zobna raztopina Zdravilna učinkovina je klorheksidin diacetat.
Marketing Authorization Holder and Manufacturer
Vožnja in upravljanje s stroji
This summary was last updated in 07-2011.
Povzetek je bil nazadnje posodobljen 07-2011.
Entacapone has been authorised in the European Union (EU) as Comtess/Comtan since 1998.
Entakapon je v Evropski uniji (EU) pod imenom Comtess/Comtan odobren od leta 1998.
The use of combinations of levodopa and carbidopa is well established, having being in use since the mid-1970s.
Uporaba kombinacij levodope in karbidope je dobro uveljavljena, in sicer od sredine sedemdesetih let prejšnjega stoletja.
Stalevo is used when these fluctuations cannot be treated with the standard combination alone.
Zdravilo Stalevo se uporablja, kadar teh fluktuacij ni mogoče zdraviti samo s standardno kombinacijo.
Other information about Stalevo
Druge informacije o zdravilu Stalevo
The full EPAR for Stalevo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Stalevo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Stalevo to on 17 October 2008.
Evropska komisija je dovoljenje za promet z zdravilom Stalevo, veljavno po vsej Evropski uniji, odobrila dne 17. oktobra 2008.
What benefit has Stalevo shown during the studies?
Kakšne koristi je zdravilo Stalevo izkazalo med študijami?
This is a summary of the European public assessment report (EPAR) for Stalevo.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Stalevo.
Stalevo tablets should be taken whole, with or without food.
Tablete zdravila Stalevo je treba zaužiti cele, s hrano ali brez nje.
What is the risk associated with Stalevo?
Kakšna tveganja so povezana z zdravilom Stalevo?
Fluctuations happen when the effects of the medication wear off and symptoms re-emerge.
Te se pojavijo, ko se učinki zdravila porazgubijo in se znova pojavijo simptomi.
Stalevo is used to treat adults with Parkinson's disease.
Zdravilo Stalevo se uporablja za zdravljenje odraslih s Parkinsonovo boleznijo.
The strength of Stalevo that the patient should use is based on the amount of levodopa they need to control their symptoms.
Jakost zdravila Stalevo, ki naj jo bolnik jemlje, temelji na količini levodope, ki jo potrebuje za nadzor nad simptomi.
They should not be used in patients with severe liver problems.
Zdravilo se ne sme uporabljati pri bolnikih s hudimi težavami z jetri.
They are linked with a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and having difficulty moving about.
Povezane so z zmanjšanjem učinka levodope, ko bolnik občuti nenadne prehode med stanjem „on“, ko se bolniki lahko premikajo, in stanjem „off“, ko imajo težave z gibanjem.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Stalevo.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Stalevo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Levodopa is converted into dopamine in the brain.
Levodopa se v možganih pretvori v dopamin.
The Committee recommended that Stalevo be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Stalevo odobri dovoljenje za promet.
It is available as a range of tablets in seven strengths, containing 50 to 200 mg levodopa and 12.5 to 50 mg carbidopa.
Na voljo je v obliki tablet v sedmih jakostih, ki vsebujejo od 50 do 200 mg levodope in 12,5 do 50 mg karbidope.
For more information about treatment with Stalevo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Stalevo preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Having all three substances in the same tablet can lower the number of tablets the patients have to take and help them stick to treatment.
Ker so vse tri učinkovine v isti tableti, je število tablet, ki jih mora bolnik zaužiti, manjše, kar jim pomaga držati se režima zdravljenja.
All of the tablets contain 200 mg entacapone
Vse tablete vsebujejo 200 mg entakapona.
The studies showed that Stalevo is bioequivalent to the separate tablets.
Študije so pokazale, da je zdravilo Stalevo biološko enakovredno tabletam z ločenimi zdravilnimi učinkovinami.
All of the active substances in Stalevo work to restore the levels of dopamine in the parts of the brain that control movement and co-ordination.
Vse zdravilne učinkovine v zdravilu Stalevo delujejo tako, da ponovno vzpostavijo ravni dopamina v tistih delih možganov, ki nadzirajo gibe in koordinacijo.
Parkinson's disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Parkinsonova bolezen je napredujoča bolezen možganov, ki povzroči tresenje, počasno gibanje in okorelost mišic.
The maximum daily dose of Stalevo is 10 tablets, except for the tablets containing 200 mg levodopa and 50 mg carbidopa, for which the maximum daily dose is seven tablets.
Največji dnevni odmerek zdravila Stalevo je 10 tablet, razen pri tabletah, ki vsebujejo 200 mg levodope in 50 mg karbidope, pri katerih je največji dnevni odmerek sedem tablet.
phaeochromocytoma (a tumour of the adrenal gland); a history of neuroleptic malignant syndrome (a dangerous nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres).
feokromocitomom (tumorjem nadledvične žleze); anamnezo nevroleptičnega malignega sindroma (nevarne bolezni živčnega sistema, ki jo običajno povzročijo antipsihotična zdravila) ali rabdomiolizo (razgradnjo mišičnega tkiva).
The company used some of the data from Comtess/Comtan to support the use of Stalevo and presented data from the published literature for levodopa and carbidopa.
Družba je v podporo uporabi zdravila Stalevo uporabila nekatere podatke o zdravilu Comtess/Comtan in predstavila podatke iz objavljene literature o levodopi in karbidopi.
Stalevo must not be used together with other medicines that belong to the group ‘monoamine oxidase inhibitors' (a type of antidepressant).
Zdravilo Stalevo se ne sme uporabljati skupaj z drugimi zdravili, ki spadajo v skupino zaviralcev monoaminooksidaze (vrsta antidepresivov).
The most common side effects with Stalevo (seen in more than 1 patient in 10) are dyskinesia (uncontrollable movements), aggravated Parkinsonism (worsening of Parkinson's disease), nausea (feeling sick) and harmless urine discoloration.
Najpogostejši neželeni učinki zdravila Stalevo (opaženi pri več kot 1 bolniku od 10) so diskinezija (nekontrolirani gibi), poslabšanje parkinsonizma (Parkinsonove bolezni), slabost in neškodljivo razbarvanje urina.
In patients with Parkinson's disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases.
Pri bolnikih s Parkinsonovo boleznijo začnejo celice v možganih, ki tvorijo živčni prenašalec dopamin, odmirati, količina dopamina v možganih pa se zmanjša.
Stalevo is a medicine that contains three active substances: levodopa, carbidopa and entacapone.
Stalevo je zdravilo, ki vsebuje tri zdravilne učinkovine: levodopo, karbidopo in entakapon.
Stalevo should not be used in people who may be hypersensitive (allergic) to levodopa, carbidopa, entacapone or any of the other ingredients.
Zdravila Stalevo ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) levodopo, karbidopo, entakapon ali katero koli drugo sestavino zdravila.
Both carbidopa and entacapone block some of the enzymes that are involved in the breakdown of levodopa in the body: carbidopa blocks the enzyme dopa decarboxylase, and entacapone blocks the enzyme catechol-O-methyl transferase (COMT).
Karbidopa in entakapon zavirata nekatere encime, ki sodelujejo pri razgrajevanju levodope v telesu: karbidopa zavira encim dopa dekarboksilazo, entakapon pa zavira encim katehol-O-metiltransferazo (COMT).
Why has Stalevo been approved?
Zakaj je bilo zdravilo Staleva odobreno?
Each Stalevo tablet contains one complete dose of levodopa, in seven strengths, with corresponding amounts of carbidopa and entacapone to improve its effectiveness.
Vsaka tableta zdravila Stalevo vsebuje en poln odmerek levodope v sedmih jakostih, za izboljšanje njene učinkovitosti pa še ustrezne količine karbidope in entakapona.
For the full list of all side effects reported with Stalevo, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Stalevo, glejte navodilo za uporabo.
Stalevo must not be used in patients with: severe liver disease; narrow-angle glaucoma (increased pressure within the eye);
Zdravila Stalevo ne smejo uporabljati bolniki: s hudimi obolenji jeter; glavkomom z zaprtim zakotjem (povečan pritisk v očesu);
Levodopa/carbidopa/entacapone
Povzetek EPAR za javnost levodopa/karbidopa/entakapon
Stalevo is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson's disease) but are having ‘fluctuations' towards the end of the period between two doses of their medication.
Zdravilo Stalevo se uporablja pri bolnikih, ki se zdravijo s kombinacijo levodope in zaviralca dopa dekarboksilaze (dveh običajnih zdravil za Parkinsonovo bolezen), pri katerih pa se proti koncu obdobja med dvema odmerkoma zdravila pojavijo fluktuacije.
What is Stalevo used for?
Za kaj se zdravilo Stalevo uporablja?
The company carried out ‘bioequivalence' studies to show that taking Stalevo produces the same levels of levodopa, carbidopa and entecapone in the blood as taking separate tablets containing entacapone and the combination of levodopa and carbidopa.
Izvedla je tudi bioekvivalenčne študije, da bi dokazala, da so ravni levodope, karbidope in entekapona v krvi pri jemanju zdravila Stalevo enake kot pri jemanju zdravilnih učinkovin v ločenih tabletah, od katerih ene vsebujejo entakapon, ter v kombiniranih tabletah, ki vsebujejo levodopo in karbidopo.
The CHMP decided that Stalevo's benefits are greater than its risks for the treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment.
CHMP je zaključil, da so koristi zdravila Stalevo pri zdravljenju bolnikov s Parkinsonovo boleznijo in motoričnimi fluktuacijami ob koncu odmernega obdobja, ki jih zdravljenje z levodopo/zaviralci dopa dekarboksilaze ne stabilizira, večje od z njim povezanih tveganj.
How does Stalevo work?
Kako zdravilo Stalevo deluje?
They should be used with caution in patients with mild to moderate problems with their liver or severe problems with their kidneys.
Bolniki z blagimi do zmerno resnimi težavami z jetri ali hudimi težavami z ledvicami morajo tablete jemati previdno.
How has Stalevo been studied?
Kako je bilo zdravilo Stalevo raziskano?
How is Stalevo used?
Kako se zdravilo Stalevo uporablja?
This helps to improve the symptoms of Parkinson's disease, such as stiffness and slowness of movement.
Posledično ostane levodopa aktivna dlje časa, kar pomaga izboljšati simptome Parkinsonove bolezni, kot sta okorelost mišic in počasnost gibov.
What is Stalevo?
Kaj je zdravilo Stalevo?
See the Summary of Product Characteristics (also part of the EPAR) for full instructions on how patients should be switched to Stalevo, and on how the dose is adjusted during treatment.
Za vsa navodila o tem, kako naj bolniki preidejo na jemanje zdravila Stalevo in kako je treba odmerek med zdravljenjem prilagajati, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
These combinations are not covered in this summary.
Teh kombinacij ta povzetek ne zajema.
Moreover, the intended use does not require medical supervision.
Poleg tega namenska uporaba ne zahteva zdravniškega nadzora.